Received by email:

File: Abattis_News_Release_-_Announce_MOU_with_Experion_-_Nov 1.doc


ABATTIS ANNOUNCES NEGOTIATIONS WITH EXPERION
Vancouver, BC - November 1, 2013 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FL
--->U), announces that it has begun negotiations with Experion Biotechnologies Inc. ("Experion") regarding a memorandum of
---> understanding (the "MOU") signed earlier this month relating to the establishment of a collaborative relationship in 
--->areas of licensing and consulting.  
The MOU will serve as a basis for the negotiation of definitive agreements (each, a "Definitive Agreement") relating t
--->o the future development and implementation by the parties of:
Good Manufacturing Processes and Standard Operating Procedures for Marihuana Medical Purposes Regulations;
establishing Experion as a licensed producer; 
the development and implementation of a means to dispense to clients as put forth in the Marihuana Medical Purposes Re
--->gulations; 
licensing; and,
distribution. 
The first Definitive Agreement being negotiated will be for the exchange set out below, conditional upon Experion beco
--->ming a licensed producer:
Experion to issue to Abattis, the number of shares equal to 15% of its issued and outstanding common shares (the "Expe
--->rion Shares.")  The Experion Shares are to have dividend rights attached such that Abattis will be entitled to receive
---> a portion of the net profits of Experion pro rata with Abattis' equity ownership in Experion, on an annual basis.
Abattis to issue to Experion 200,000 common shares (the "Abattis Shares") and the following options:
200,000 options exercisable for 1 year at an exercise price of $0.10 per share;
200,000 options exercisable for 2 years at an exercise price of $0.20 per share; and,
200,000 options exercisable for 3 years at an exercise price of $0.30 per share
"Our collaborative relationship with Experion is an exciting development for Abattis.  Experion has submitted its appl
--->ication to Health Canada and we look forward to it becoming a licensed producer in the near future.  Together, we will
---> work toward maximizing the value of that license for both of our companies and for medical marihuana patients by ensu
--->ring high quality products, strict adherence to the legal regime and mutual support for producing and distributing a r
--->eliable, quality product," said Mike Withrow, President and CEO of Abattis. "Experion Biotechnologies is pleased with 
--->achieving this first of many milestones with Abattis and we look forward to solidifying our relationship in the very n
--->ear future" said Sean MacNeil, Director of Communications for Experion.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, lic
--->ensing and marketing proprietary ingredients and bio-similar compounds for use in Pharmaceuticals, Nutraceutical, Cosm
--->etic and Animal Nutrition markets. The Company also has a deep pipeline of proprietary products ready for sale in high
---> growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.a
--->battis.com.
About Experion Biotechnologies Inc.
Experion is a Botanical Drug Company with plans for tissue culture, cultivation and sales of Medicinal Marijuana in Ca
--->nada under the new MMPR Rules from Health Canada which comes into effect on April 1 2014.  ON BEHALF OF THE BOARD


	"Mike Withrow"			
Michael Withrow President & CEO

For further information, contact the Company's CEO, Michael Withrow at 778-896-6536
or at mike.withrow@abattis.com.


NEITHER THE CNSX EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUAC
--->Y OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimat
--->e", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-l
--->ooking statements.  
Although the Company believes that the expectations and assumptions on which the forward-looking statements are based 
--->are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no 
--->assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, b
--->y their very nature they involve inherent risks and uncertainties. Forward-looking statements in this press release in
--->clude that (a) the parties will negotiate and enter into definitive agreements, (b) Experion will become a licensed pr
--->oducer (c) Experion will issue a number of shares equal to 15% of Experion's issued and outstanding shares, (d) the Ex
--->perion Shares will have dividend rights attached (e) Abattis will issue 200,000 of its common shares to Experion, (f) 
--->Abattis will grant a total of 600,000 options to Experion for the purchase of additional Abattis common shares and (g)
---> that the parties will work together to maximize the value of the license by ensuring high quality products, strict ad
--->herence to the legal regime and mutual support for producing and distributing a reliable, quality product.  These stat
--->ements speak only as of the date of this press release. Actual results could differ materially from those currently an
--->ticipated due to a number of factors and risks including various risk factors discussed in the Company's Management's 
--->Discussion and Analysis for the nine months ended June 30, 2013 and filed on August 29, 30, 2013 and for the year ende
--->d September 30, 2012 and filed on January 28, 2013 under the Company's profile on www.sedar.com.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DA
--->TE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTA
--->NCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY M
--->AY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME.